[The effect of treatment with human recombinant erythropoietin on the functional status of patients on maintenance hemodialysis].

As many as ten patients with terminal uremia on maintenance hemodialysis (MH) performed from 11 to 52 months (28 +/- 4 on the average) were treated with recombinant human erythropoietin (rhERP) manufactured by Cilag (Switzerland). The preparation was injected i.v.

[Role of electrical interference between adjacent portions of the myocardium in the origin of arrhythmias].

Excitation propagation was studied in the papillary muscle of cat's heart and on a mathematical model of homogenous fibre, considerable inhomogeneity being created in the duration of the action potential (DAP) in the left and right part of the object studied. Gradual changes in DAP were observed during excitation propagation period, therefore rough differences in DAP of neighbouring myocardial areas may be excluded. No arrhythmia was observed.